Use of a slow-release intravitreal clindamycin implant for the management of ocular toxoplasmosis
Purpose: To report the first patient with ocular toxoplasmosis treated with a slow-release biodegradable intravitreal clindamycin implant. Observations: A 39-year-old human immunodeficiency virus (HIV)-positive woman with recurrent toxoplasmic retinochoroiditis and vitritis for whom oral medication...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-06-01
|
| Series: | American Journal of Ophthalmology Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S245199362100102X |
| _version_ | 1819067130739425280 |
|---|---|
| author | Rodrigo Jorge, MD, PhD Igor Neves Coelho, MD Armando Silva-Cunha, PhD Gabriella Maria Fernandes Cunha, PhD Ingrid U. Scott, MD, MPH Silvia Ligório Fialho, PhD João Marcello Furtado, MD, PhD |
| author_facet | Rodrigo Jorge, MD, PhD Igor Neves Coelho, MD Armando Silva-Cunha, PhD Gabriella Maria Fernandes Cunha, PhD Ingrid U. Scott, MD, MPH Silvia Ligório Fialho, PhD João Marcello Furtado, MD, PhD |
| author_sort | Rodrigo Jorge, MD, PhD |
| collection | DOAJ |
| description | Purpose: To report the first patient with ocular toxoplasmosis treated with a slow-release biodegradable intravitreal clindamycin implant. Observations: A 39-year-old human immunodeficiency virus (HIV)-positive woman with recurrent toxoplasmic retinochoroiditis and vitritis for whom oral medication was medically contraindicated was treated with an intravitreal slow-release clindamycin implant and three monthly intravitreal injections of clindamycin and dexamethasone. Serial ophthalmologic examinations demonstrated gradual, complete resolution of posterior uveitis and healing of the retinochoroidal lesion with cicatricial changes, as well as gradual improvement of cells in the anterior chamber. There was no significant change in electroretinography waves after treatment with the implant. The presence of the implant, or part of it, was detectable in the vitreous cavity for 4 months. To date, the patient has been monitored for 30 months, and there has been no reactivation of ocular toxoplasmosis. Conclusion: The slow-release clindamycin implant was safe for intravitreal use in this patient and may have contributed to the long-term control of toxoplasmosis chorioretinitis. |
| first_indexed | 2024-12-21T16:13:22Z |
| format | Article |
| id | doaj.art-b0399406ce904dc79ea56b9adc83b2a5 |
| institution | Directory Open Access Journal |
| issn | 2451-9936 |
| language | English |
| last_indexed | 2024-12-21T16:13:22Z |
| publishDate | 2021-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | American Journal of Ophthalmology Case Reports |
| spelling | doaj.art-b0399406ce904dc79ea56b9adc83b2a52022-12-21T18:57:45ZengElsevierAmerican Journal of Ophthalmology Case Reports2451-99362021-06-0122101093Use of a slow-release intravitreal clindamycin implant for the management of ocular toxoplasmosisRodrigo Jorge, MD, PhD0Igor Neves Coelho, MD1Armando Silva-Cunha, PhD2Gabriella Maria Fernandes Cunha, PhD3Ingrid U. Scott, MD, MPH4Silvia Ligório Fialho, PhD5João Marcello Furtado, MD, PhD6Department of Ophthalmology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil; Corresponding author. Department of Ophthalmology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, 3900 Bandeirantes Ave, 14049-900, Brazil.Department of Ophthalmology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, BrazilFaculty of Pharmacy, Minas Gerais Federal University, Belo Horizonte, Minas Gerais, BrazilFaculty of Pharmacy, Minas Gerais Federal University, Belo Horizonte, Minas Gerais, BrazilDepartments of Ophthalmology and Public Health Sciences, Penn State College of Medicine, Hershey, PA, USAPharmaceutical and Biotechnological Development, Ezequiel Dias Foundation, Belo Horizonte, Minas Gerais, BrazilDepartment of Ophthalmology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, BrazilPurpose: To report the first patient with ocular toxoplasmosis treated with a slow-release biodegradable intravitreal clindamycin implant. Observations: A 39-year-old human immunodeficiency virus (HIV)-positive woman with recurrent toxoplasmic retinochoroiditis and vitritis for whom oral medication was medically contraindicated was treated with an intravitreal slow-release clindamycin implant and three monthly intravitreal injections of clindamycin and dexamethasone. Serial ophthalmologic examinations demonstrated gradual, complete resolution of posterior uveitis and healing of the retinochoroidal lesion with cicatricial changes, as well as gradual improvement of cells in the anterior chamber. There was no significant change in electroretinography waves after treatment with the implant. The presence of the implant, or part of it, was detectable in the vitreous cavity for 4 months. To date, the patient has been monitored for 30 months, and there has been no reactivation of ocular toxoplasmosis. Conclusion: The slow-release clindamycin implant was safe for intravitreal use in this patient and may have contributed to the long-term control of toxoplasmosis chorioretinitis.http://www.sciencedirect.com/science/article/pii/S245199362100102XToxoplasmosisClindamycinImplantIntravitrealUveitis |
| spellingShingle | Rodrigo Jorge, MD, PhD Igor Neves Coelho, MD Armando Silva-Cunha, PhD Gabriella Maria Fernandes Cunha, PhD Ingrid U. Scott, MD, MPH Silvia Ligório Fialho, PhD João Marcello Furtado, MD, PhD Use of a slow-release intravitreal clindamycin implant for the management of ocular toxoplasmosis American Journal of Ophthalmology Case Reports Toxoplasmosis Clindamycin Implant Intravitreal Uveitis |
| title | Use of a slow-release intravitreal clindamycin implant for the management of ocular toxoplasmosis |
| title_full | Use of a slow-release intravitreal clindamycin implant for the management of ocular toxoplasmosis |
| title_fullStr | Use of a slow-release intravitreal clindamycin implant for the management of ocular toxoplasmosis |
| title_full_unstemmed | Use of a slow-release intravitreal clindamycin implant for the management of ocular toxoplasmosis |
| title_short | Use of a slow-release intravitreal clindamycin implant for the management of ocular toxoplasmosis |
| title_sort | use of a slow release intravitreal clindamycin implant for the management of ocular toxoplasmosis |
| topic | Toxoplasmosis Clindamycin Implant Intravitreal Uveitis |
| url | http://www.sciencedirect.com/science/article/pii/S245199362100102X |
| work_keys_str_mv | AT rodrigojorgemdphd useofaslowreleaseintravitrealclindamycinimplantforthemanagementofoculartoxoplasmosis AT igornevescoelhomd useofaslowreleaseintravitrealclindamycinimplantforthemanagementofoculartoxoplasmosis AT armandosilvacunhaphd useofaslowreleaseintravitrealclindamycinimplantforthemanagementofoculartoxoplasmosis AT gabriellamariafernandescunhaphd useofaslowreleaseintravitrealclindamycinimplantforthemanagementofoculartoxoplasmosis AT ingriduscottmdmph useofaslowreleaseintravitrealclindamycinimplantforthemanagementofoculartoxoplasmosis AT silvialigoriofialhophd useofaslowreleaseintravitrealclindamycinimplantforthemanagementofoculartoxoplasmosis AT joaomarcellofurtadomdphd useofaslowreleaseintravitrealclindamycinimplantforthemanagementofoculartoxoplasmosis |